Journal
CLINICAL CANCER RESEARCH
Volume 11, Issue 18, Pages 6634-6640Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-05-0436
Keywords
-
Categories
Funding
- NCI NIH HHS [P50 CA90949, K24CA080908, CA77839, CA68485, CA076321] Funding Source: Medline
- NCRR NIH HHS [RR00095] Funding Source: Medline
- NIDDK NIH HHS [DK48831] Funding Source: Medline
- NIGMS NIH HHS [GM15431] Funding Source: Medline
Ask authors/readers for more resources
Cyclooxygenase-2,(COX-2) catalyzes the rate-limiting.step in prostaglandin (PG) synthesis and is, overexpressed in 70% to 90% of non -small cell lung,cancers (NSCLC). Preclinical studies suggest inhibition of COX-2 can enhance the cytotoxic effect of docetaxel. To test this concept clini- cally, we,administered celecoxib (400 mg p.o. twice daily) plus docetaxel (75, mg/m(2) every 3 weeks) to a,cohort of patients with recurrent, previously treated NSCLC. Patients first received single agent celecoxib for 5 to 10 days to ascertain the effectiveness of COX-.2 inhibition, which was determined by measuring pre- and post-celecoxib levels of urinary 11 alpha-hydroxy-9,15-dioko2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M),the major metabolite of prostaglandin E-2 (PGE(2)). We enrolled 156 patients (35 men, 21 women; median age, 61 years). All patients had received at least one prior chemotherapy regimen. The overall response rate was 11% and median survival was 6 months, similar to that observed with docetaxel alone. Pre-celecoxib urinary PGEM decreased from a mean level of 27.2 to 12.2- ng/mg Cr after 5 to 10 days of celecoxib (P= 0.001). When grouped by quartile, patients with the greatest proportional decline in urinary PGEM levels experienced a longer survival compared to those with,no change or an increase in PGE-M (14.8 versus 6.3 versus 5.0 months). Our data suggest that combining celecoxib with docetaxel using the doses and schedule employed does not improve survival in unselected patients with recurrent, previously treated NSCLC. However, in light of the apparent survival prolongation in the subset- with a marked decline in urinary PGE-M levels, further investigation of strategies designed to decrease PGE(2) synthesis in NSCLC seems warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available